Pharming redeems final tranche of convertible bond
(Thomson Reuters ONE) -
Leiden, The Netherlands, June 13, 2012. Biotech company Pharming Group NV
("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that it has
redeemed the final tranche of its ?8.4 million convertible bond. A total of
45,580,468 shares will be issued today to the bondholders under the terms and
conditions of the bond, as announced in Pharming's press release on December
23, 2011, and following the approval of the increase in the Company's authorised
share capital during the extraordinary general meeting of shareholders, which
was held on February 3, 2012.
As of today, the number of outstanding shares has increased from 625,082,077 to
670,662,545.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of unmet
medical needs. RUCONEST® (RHUCIN® in non-European territories) is a recombinant
human C1 inhibitor approved for the treatment of angioedema attacks in patients
with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein, and is
distributed in the EU by Swedish Orphan Biovitrum (OMX: SOBI). RHUCIN® is
partnered with Santarus, Inc (NASDAQ: SNTS) in North America where the drug is
undergoing Phase III clinical development. The product is also being evaluated
for follow-on indications in the areas of transplantation and reperfusion
injury. The advanced technologies of the Company include innovative and
validated platforms for the production of protein therapeutics, technology and
processes for the purification and formulation of these products. A feasibility
study, using the validated transgenic rabbit platform, aimed at the development
of recombinant Factor VIII for the treatment of Haemophilia A is underway with
partner, Renova Life, Inc. Additional information is available on the Pharming
website, www.pharming.com. To download the Pharming Group Investor Relations
App, click here.
This press release contains forward looking statements that involve known and
unknown risks, uncertainties and other factors, which may cause the actual
results, performance or achievements of the Company to be materially different
from the results, performance or achievements expressed or implied by these
forward looking statements.
Contact
Pharming
Sijmen de Vries, CEO: T: +31 (0)71 524 7400
Karl Keegan, CFO: T: +31 (0)71 524 7400
FTI Consulting
Julia Phillips, T: +44 (0)207 269 7187
John Dineen, T: +44 (0)207 269 7193
# # #
Press release (PDF):
http://hugin.info/132866/R/1619265/517164.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Pharming Group N.V. via Thomson Reuters ONE
[HUG#1619265]
Unternehmensinformation / Kurzprofil:
Datum: 13.06.2012 - 08:00 Uhr
Sprache: Deutsch
News-ID 155921
Anzahl Zeichen: 3439
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 188 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pharming redeems final tranche of convertible bond"
steht unter der journalistisch-redaktionellen Verantwortung von
Pharming Group N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
